AIM: To investigate the clinical performances of rapid stool test (ImmunoCard STAT HpSA, Meridian Diagnostic Inc.) in the evaluation of eradication therapy of H pylori and to compare it with a well-known and validated laboratory stool test (Amplified IDEA Hp StAR, Dako). METHODS: Stool samples of 122 patients were evaluated after eradication therapy of H pylori. H pylori status was assessed by 13C-urea breath test (UBT). Stool specimens were tested using either the rapid immunoassay kit or the laboratory immunoassay kit. RESULTS: Forty-three patients were infected and 79 non-infected. Sensitivity and specificity of ImmunoCard STAT and Hp StAR were 58.14% and 76.4%, and 97.47% and 98.73%, respectively (P > 0.05). Overall agreement between the two tests was 92.6% (113 of 122 cases). CONCLUSION: ImmunoCard STAT seems to have rather low performances, and it cannot be regarded as a reliable tool in the post-treatment setting. Also Hp StAR cannot be recommended to confirm H pylori eradication after treatment.
AIM: To investigate the clinical performances of rapid stool test (ImmunoCard STAT HpSA, Meridian Diagnostic Inc.) in the evaluation of eradication therapy of H pylori and to compare it with a well-known and validated laboratory stool test (Amplified IDEA Hp StAR, Dako). METHODS: Stool samples of 122 patients were evaluated after eradication therapy of H pylori. H pylori status was assessed by 13C-urea breath test (UBT). Stool specimens were tested using either the rapid immunoassay kit or the laboratory immunoassay kit. RESULTS: Forty-three patients were infected and 79 non-infected. Sensitivity and specificity of ImmunoCard STAT and Hp StAR were 58.14% and 76.4%, and 97.47% and 98.73%, respectively (P > 0.05). Overall agreement between the two tests was 92.6% (113 of 122 cases). CONCLUSION: ImmunoCard STAT seems to have rather low performances, and it cannot be regarded as a reliable tool in the post-treatment setting. Also Hp StAR cannot be recommended to confirm H pylori eradication after treatment.
Authors: Nese Kaklikkaya; Remzi A Akdogan; Orhan Ozgur; Dogan Y Uzun; Umit Cobanoglu; Ugur Dinc; Erdal Gungor; Pinar A Dabanca; Mehmet Arslan; Faruk Aydin; Murat Erturk Journal: Saudi Med J Date: 2006-06 Impact factor: 1.484
Authors: L Trevisani; S Sartori; M R Rossi; M Ruina; V Matarese; S Gullini; V Abbasciano Journal: Aliment Pharmacol Ther Date: 2005-02-15 Impact factor: 8.171
Authors: P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers Journal: Gut Date: 2006-12-14 Impact factor: 23.059
Authors: J Domínguez; M Forné; S Blanco; C Prat; N Galí; I Latorre; J M Viver; V Ausina Journal: Aliment Pharmacol Ther Date: 2006-06-15 Impact factor: 8.171
Authors: Ki Tae Kwon; Dong Seok Lee; In Kwon Chung; Min Jae Park; Chang Keun Park; Chang Min Cho; Won Young Tak; Young Oh Kweon; Sung Kook Kim; Yong Hwan Choi Journal: Korean J Gastroenterol Date: 2004-10
Authors: N L Arents; A A van Zwet; J C Thijs; A de Jong; M O Pool; J H Kleibeuker Journal: Eur J Gastroenterol Hepatol Date: 2001-04 Impact factor: 2.566